Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$4.1BCash on Hand
CF+ Cash Runway
Follow TEVA by emailGet an email when TEVA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about TEVA, unsubscribe in one click. Privacy
📣 What TEVA Says Is Next
this year · “The FDA accepted ecopipam's (EBS-101) NDA for review, positive Phase 2a results were reported for anti-IL-15 (TEV-‘408) in Celiac disease, and the anti-IL-15 program is planned to advance into Phase 2b development in vitiligo later this year.”
Company press release, Nov 3, 2026 · SEC filing
Q4 2026 · “Teva reported positive Phase 2a results for anti-IL-15 (TEV-‘408) in Celiac disease, and is targeting to begin Phase 2b in vitiligo in Q4 2026.”
Company press release, Nov 3, 2026 · SEC filing
Q1 2027 · “Innovative pipeline successes strengthen Teva’s longer-term growth profile with the potential to launch at least one product per year over five years: The U.S. FDA accepted the ecopipam New Drug Application (NDA) for review, advancing a potential first-in-class selective D1 receptor anti-agonist for Tourette syndrome in the pediatric population, with an action date expected in Q1 2027.”
Company press release, Nov 3, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 3, 2026 ·
Earnings Teva reported Q3 2026 revenues of $4.4 billion, down 2% year-over-year, with GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.86. Key innovative brands grew 33% in local currency to about $1.1 billion, and 2026 revenue outlook was raised to $16.7–$17.0 billion. Form 8-K · SEC filing · Press release
Nov 3, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 29, 2026 ·
Leadership Teva's board elected Dr. David J. Brailer as an independent director, effective November 3, 2026, until the 2027 annual meeting. He will join the Human Resources and Compensation and Compliance Committees. Form 8-K · SEC filing
Sep 16, 2026 ·
Financing Teva's subsidiaries issued €1.0 billion of 4.250% notes due 2033, €500 million of 4.625% notes due 2036, $1.0 billion of 5.500% notes due 2034, $1.0 billion of 5.750% notes due 2037 and $1.2 billion of 5.250% notes due 2032, guaranteed by Teva. Proceeds will partly fund conditional redemptions of existing notes. Form 8-K · SEC filing
Sep 14, 2026 ·
Listing Teva began trading its ordinary shares on the NYSE under the TEVA ticker on September 14, 2026, replacing its American depositary shares. The ADS program terminated that day, with each ADS exchanged for one ordinary share. Shares continue to trade on the Tel Aviv Stock Exchange under the same symbol. Form 8-K · SEC filing
Sep 11, 2026 ·
Financing Teva priced about $4.9 billion equivalent of senior notes across five tranches, with a 2032 USD note at 98.993% of par and a 2037 USD note at 98.520%. Net proceeds will fund conditional redemptions of several existing notes, with settlement expected on or about September 16, 2026. Form 8-K · SEC filing · Press release
Sep 11, 2026 ·
Financing Teva's finance subsidiaries are offering about $4.9 billion equivalent of senior notes in four tranches: €1,000,000,000 of 4.250% notes due 2033, €500,000,000 of 4.625% notes due 2036, $1,000,000,000 of 5.500% notes due 2034, $1,000,000,000 of 5.750% notes due 2037, and $1,200,000,000 of 5.250% notes due 2032. Form 424B5 · SEC filing
Sep 8, 2026 ·
Financing Teva Pharmaceutical Finance Netherlands II, III and IV propose senior notes in euro and US dollar tranches due 2032 through 2037, fully guaranteed by Teva Pharmaceutical Industries. Amounts, coupons and prices are left blank in this preliminary prospectus supplement. Form 424B5 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jan 2023 · Phase 1 · Results Expected · A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b) Registry primary completion date, not a results date
Dec 2020 · Phase 3 · Results Expected · Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip Registry primary completion date, not a results date
Jan 2020 · Phase 2 · Results Expected · Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee Registry primary completion date, not a results date
Jan 2020 · Phase 1 · Results Expected · To Assess the Patients' Ability to Self-Administer Fasinumab Registry primary completion date, not a results date
Dec 2019 · Phase 3 · Results Expected · Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or… Registry primary completion date, not a results date
Sep 2019 · Phase 3 · Results Expected · A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not TEVA's own candidates): Armodafinil, Naproxen, Filgrastim, Somatropin, Decitabine, Cytarabine, Celecoxib, Azithromycin, Azacitidine, Caffeine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
TEVA holds $4.1B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Share count 1,166,826,784 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full TEVA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TEVA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.